BiotechTV - News
BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Jefferies London 2026: IDEAYA Biosciences Founder & CEO Yujiro Hata shares an update on darovasertib, which is in front of FDA for Uveal Melanoma, and talks DLL3 and PRMT5
He describes the darovasertib filing, which IDEAYA hopes will be for all metastatic uveal melanoma patients. Plus, what makes DLL3 a compelling target, and how interest in PRMT5 has especially taken off given how prevalent MTAP deletions are in pancreatic cancer.
Nov 18
11 min
Jefferies London 2026: Forbion, the most active lead investor in private biotech financing rounds globally last year, raised €2.3 billion across two new funds last month
Co-Owner and Managing Partner Sander Slootweg discusses the new funds and what kind of companies the funds might be deployed towards. He also shares his ideas and recommendations on how to make Europe more competitive in life sciences and keep companies in the region, and gives his take on the sector's outlook in 2027.
Nov 18
12 min
Jefferies London 2026: APOL1-mediated kidney disease affects over 1 million people in the United States - Maze Therapeutics hopes to deliver a solution
CEO Jason Coloma describes the unmet need in this area - which affects younger people compared to most other chronic kidney conditions. He walks us through MZE829, which just completed enrollment the phase 2 HORIZON trial and will have data in early 2027.
Nov 18
13 min
Jefferies London: When Celgene's powerhouse myeloma treatments emerged, it wasn't known that they were protein degraders. With today's advances in science, C4 aims to have a best in class degrader
President and CEO Andrew Hirsch describes the concept of protein degraders in general, and the paper that sparked the creation of C4 as a company. He discusses the company's registration intended trial, and another one in combination with a T-cell engager from Pfizer.
Nov 18
12 min
Jefferies London 2026: Zealand Pharma CEO Adam Steensberg gives an update on the company's amylin program and comments on recent data from its Boehringer partnered glucagon/GLP-1
He shares his strong belief that for most people taking obesity medicines going forward, tolerability could be the most important factor of choice, which is amylin's strong suit.
Nov 18
14 min
Jefferies London 2026: Erasca is racing to be the next big story in the RAS space (in both pancreatic and lung) and believes it may have a best in class asset with high potency
CEO Jonathan Lim descrbies the profile of ERAS-0015 and the data the company has derived up to this point. A phase 3 study is planned in 1st line pancreatic cancer in the early part of 2027 and two in lung later in the year. He also discusses combinations, including with Erasca's own KRAS inhibitor.
Nov 18
13 min
Jefferies London 2026: The phase 3 OPERA-01study of Olema's CERAN + SERD, palazestrant, is setting up to be one of biotech's key readouts and is quickly approaching and scheduled to read in 1Q27
CEO Sean Bohen reminds us of the mechanism and the design of this monotherapy study, which is in the 2/3 line ER+/HER2 metastatic breast cancer setting. He also discusses why he believes the OPERA-02 study in 2nd line in combo with a CDK 4/6 can succeed where a competitor failed earlier this year.
Nov 18
11 min
Jefferies London 2026: Marea Therapeutics' CEO Josh Lehrer describes the ANGPTL4 target for targeting triglycerides (Marea is first in class) and compares and contrasts it to ANGPTL3 and APOE3
The company recently presented phase 2b data at AHA and published in NEJM. Dr. Lehrer also discusses the company's acromegaly program, and more.
Nov 17
9 min
Jefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them
They discuss Roivant's structure and programs (a top holding of Affinity's) and how different investors view companies different ways. Plus, the ups and downs of biotech, and why it is rare for smaller biotech companies to grow into larger entities over the long run.
Nov 17
19 min
Jefferies London 2026: With two FDA filings under review and other programs in late stage, Praxis is in a pivotal moment - CEO Marcio Souza updates us on all the moving pieces
He shares an update on the ulixacaltamide and relutrigine filings, and how he thinks about potential commercialization opportunities. Plus, late stage readouts to watch out for.
Nov 17
14 min
Load more